General practitioners' perspectives on blood biomarkers for Alzheimer's disease.

BACKGROUND: Alzheimer's disease (AD) blood biomarkers could improve the diagnostic process for patients with cognitive complaints presenting to primary care. We investigated general practitioners' (GPs') perspectives on facilitating and hindering factors associated with the use and implementation of AD blood biomarkers. METHOD: In this qualitative, semi-structured interview study, we used purposive sampling to recruit a heterogeneous group of 18 Dutch GPs. Qualitative data analysis of interview transcripts was based on the Theoretical Domains Framework. RESULTS: GPs believed that AD blood biomarkers could have both positive and negative consequences. Mentioned positive consequences included facilitating an accessible diagnostic process, clarity about the etiology, and life planning. Mentioned negative consequences were imposing a psychological burden on patients and possible AD over- or underdiagnosis. CONCLUSION: While AD blood biomarkers may have potential benefits according to GPs, additional evidence, definition of context of use and logistics, and adoption of guidelines are needed for eventual implementation. Highlights: GPs experience a knowledge gap regarding AD and AD blood biomarkersAD blood biomarkers could inform GPs, enabling decision-making in primary careGPs perceive various harms and benefits associated with the use of AD biomarkersInformation, education and guidelines are key factors for successful implementation.